

Date: January 20, 2025

To,
Sr. General Manager
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400001

BSE Scrip Code: 544319

To,
Sr. General Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

NSE Symbol: SENORES

Dear Sir/Madam,

Subject: Intimation under Regulation 30(6) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”)- Intimation of investment through Rights Issue in Senores Pharmaceuticals Inc., Wholly Owned Subsidiary of the Company

In furtherance to the Objects of the Initial Public Offer (“IPO”) as per the prospectus of the Company dated December 24, 2024 and pursuant to Regulation 30(6) read with Schedule III Part A Para A (1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we would like to inform you that the Company has made a further investment in Senores Pharmaceuticals INC. (“SPI”), a wholly-owned subsidiary of the Company, through a rights issue.

We have enclosed herewith the details required under Regulation 30 read with Para A(1) of Part A of Schedule III of the Listing Regulations and the SEBI circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 as **Annexure -1**.

We request you to take the above information on record.

Thanking you.

For Senores Pharmaceuticals Limited

Deval Rajnikant Shah
Whole Time Director and CFO
DIN: 00332722

Encl.: As above

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com

W: www.senorespharma.com | CIN No.: U24290GJ2017PLC100263

Disclosure under Regulation 30(6) read with Para A(1) of Part A of Schedule III of the Listing Regulations and the SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

Sr. No.	Particulars	Description
1.	Name of the Target Company, details in brief such as size, turnover, etc.	Senores Pharmaceuticals INC. (“SPI”) is currently engaged in the business of development of finished formulations for regulated markets. The turnover of SPI for the financial year ended March 31, 2024 was USD 59,38,166.00.
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	SPI, being a wholly owned subsidiary is a related party of the Company. The transaction falls within the ambit of related party transactions and is at arms’ length. Except to the extent of shares held by the Company in SPI, the Company has no interest in SPI.
3.	Industry to which the entity being acquired belongs	Pharmaceuticals
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	This investment is a part of utilization of the proceeds as specified in Prospectus dated December 24, 2024 for working capital requirements of SPI.
5.	Brief details of any governmental or regulatory approvals required for the acquisition	Requisite approvals under Foreign Exchange Management Act, 1999 have been obtained.
6.	Indicative time period for completion of the acquisition	Not applicable
7.	Consideration - whether cash consideration or share swap or any other form and details of the same	Cash
8.	Cost of acquisition or the price at which the shares are acquired	Investment of USD 1,252,800 (108,000 equity shares of USD 11.60 each on rights basis).
9.	Percentage of shareholding/ control acquired and/or number of shares acquired	There will be no change in the percentage of shareholding of the Company in SPI. It will continue to remain a wholly owned subsidiary of the Company.

Senores Pharmaceuticals Limited

 1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
 Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

 P: +91 79 2999 9857 | E: info@senorespharma.com

 W: www.senorespharma.com | CIN No.: U24290GJ2017PLC100263

Sr. No.	Particulars	Description						
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	<p>SPI was incorporated on January 28, 2021 as a wholly owned subsidiary of the Company. SPI is a US based company holding the intellectual property used by the Company, specifically for its ANDA approvals and enters into agreement with the marketing partners of the Company.</p> <p>The turnover of SPI for last 3 years is given below:</p> <p style="text-align: right;">(Amount in USD)</p> <table border="1" data-bbox="847 539 1447 656"> <thead> <tr> <th data-bbox="847 539 1037 600">Mar-22</th> <th data-bbox="1037 539 1241 600">Mar-23</th> <th data-bbox="1241 539 1447 600">Mar-24</th> </tr> </thead> <tbody> <tr> <td data-bbox="847 600 1037 656">1,18,240.00</td> <td data-bbox="1037 600 1241 656">33,53,196.00</td> <td data-bbox="1241 600 1447 656">59,38,166.00</td> </tr> </tbody> </table> <p>Country of presence: United States of America</p>	Mar-22	Mar-23	Mar-24	1,18,240.00	33,53,196.00	59,38,166.00
Mar-22	Mar-23	Mar-24						
1,18,240.00	33,53,196.00	59,38,166.00						

Committed to
Global Wellness!

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com

W: www.senorespharma.com | CIN No.: U24290GJ2017PLC100263